Glycosmedia Weekly Diabetes News - 06/12/2020

Diabetes medications with cardiovascular protection as we enter a new decade

Can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives? (ABCD)

Supporting people with diabetes during the COVID-19 pandemic without face-to-face appointments

We write this article deep during the coronavirus pandemic gripping the UK. While we are not anywhere near through with this, it would appear that perhaps it is the end of the beginning (ABCD)

Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine)

The Leader study has shown that the rate of the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo (ABCD)

The impact of diabetes on COVID-19 infection

Not unexpectedly, dia­betes has been identified as posing a particular adverse risk, along with chronic renal and coronary heart disease, and such surrogate risk indicators as obesity and hypertension (Practical Diabetes)

A disease state approach to the pharmacological management of Type 2 diabetes in primary care

A position statement by Primary Care Diabetes Europe (Primary Care Diabetes)

Update on clinical screening of maturity-onset diabetes of the young (MODY)

The selection of diabetic patients for genetic testing is an ongoing challenge. Metabolic profiling, diabetes onset age, pancreatic antibodies, and C-peptide seem to be useful tools to better select patients for genetic testing (Diabetology & Metabolic Syndrome)

Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin

In DKD subjects, Linagliptin promotes an increase in CXCR4 expression on CD34 + progenitor cells with a concomitant improvement in vascular and renal parameters at 12 weeks (Cardiovascular Diabetology)